Inotiv downgraded by Lake Street with a new price target
$NOTV
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Lake Street downgraded Inotiv from Buy to Hold and set a new price target of $7.00 from $60.00 previously
Get the next $NOTV alert in real time by email
Get the next $NOTV alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $NOTV
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2024 | $11.50 → $3.75 | Buy → Hold | Jefferies |
| 2/9/2024 | $3.00 → $11.50 | Hold → Buy | Jefferies |
| 7/20/2023 | $9.00 | Overweight | Wells Fargo |
| 1/19/2023 | $10.00 → $8.00 | Buy → Hold | Jefferies |
| 1/11/2023 | $4.00 → $10.00 | Hold → Buy | Lake Street |
| 11/18/2022 | $60.00 → $7.00 | Buy → Hold | Lake Street |
| 10/4/2022 | $27.00 | Buy | Jefferies |
| 1/31/2022 | $60.00 | Buy | Lake Street |
Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Provides Business Update
Enhanced liquidity by $27.5 million through the issuance of 6.9 million common sharesFirst quarter fiscal 2025 revenue declined 11.5% to $119.9 millionConference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2025") ended December 31, 2024. Revenue by Segment (in millions of USD) Three Months EndedDecember 31, % change 2024 2023 (unaudite
Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025
WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, on Wednesday, February 5, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-579-2543 (Domestic)1-785-424-1789 (International)I
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million
WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised an additional $3.6 million in net proceeds from the optional shares in connection with its previously announced underwritten public offering of common shares. The Company issued the additional 900,000 shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the 900,000 optional shares of common stock
Inotiv downgraded by Jefferies with a new price target
Jefferies downgraded Inotiv from Buy to Hold and set a new price target of $3.75 from $11.50 previously
Inotiv upgraded by Jefferies with a new price target
Jefferies upgraded Inotiv from Hold to Buy and set a new price target of $11.50 from $3.00 previously
Wells Fargo initiated coverage on Inotiv with a new price target
Wells Fargo initiated coverage of Inotiv with a rating of Overweight and set a new price target of $9.00
Director Landman David bought $99,998 worth of shares (23,529 units at $4.25), increasing direct ownership by 15% to 176,851 units (SEC Form 4)
4 - Inotiv, Inc. (0000720154) (Issuer)
Chief Operating Officer Beattie John Gregory bought $142,500 worth of shares (30,000 units at $4.75), increasing direct ownership by 23% to 161,761 units (SEC Form 4)
4 - Inotiv, Inc. (0000720154) (Issuer)
Director Brown Nigel bought $31,950 worth of shares (7,500 units at $4.26), increasing direct ownership by 13% to 65,537 units (SEC Form 4)
4 - Inotiv, Inc. (0000720154) (Issuer)
President and CEO Leasure Robert Jr. was granted 429,730 shares, increasing direct ownership by 45% to 1,386,322 units (SEC Form 4)
4 - Inotiv, Inc. (0000720154) (Issuer)
Director Neff R Matthew was granted 39,392 shares, increasing direct ownership by 34% to 155,102 units (SEC Form 4)
4 - Inotiv, Inc. (0000720154) (Issuer)
Chief Commercial Officer Hardy Adrian was granted 25,000 shares, increasing direct ownership by 75% to 58,420 units (SEC Form 4)
4 - Inotiv, Inc. (0000720154) (Issuer)
Inotiv Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
8-K - Inotiv, Inc. (0000720154) (Filer)
SEC Form S-8 filed by Inotiv Inc.
S-8 - Inotiv, Inc. (0000720154) (Filer)
Inotiv Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Inotiv, Inc. (0000720154) (Filer)
Universal Display Corporation Announces the Appointment of New Board Members
Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti
Inotiv, Inc. Announces Changes to its Board Composition
WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board's succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board. Ms. Coelho is the CFO at Gamida Cell Ltd., a public, commercial stage biotech company. Previously, Ms. Coelho was Executive Vice President, CFO and Chief Business Development Offic
Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025
WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, on Wednesday, February 5, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-579-2543 (Domestic)1-785-424-1789 (International)I
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update
— Enhanced liquidity through issuance of Second Lien Notes — Obtained amendment to credit agreement and extended note payable — Fourth quarter fiscal 2024 revenue down 7.3% to $130.4 million — Full year fiscal 2024 revenue down 14.3% to $490.7 million — Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q4 FY 2024") and twelve months ("FY 2024") ended Septem
Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-267-6316 (Domestic)1-203-518-9783 (In
SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)